014339AA3
Alder Biopharmaceuticals Inc
Could not find a ticker for this position, may be a filing error
A biotechnology company that develops therapeutic antibodies, best known for creating the migraine-prevention medicine eptinezumab (brand name Vyepti), the first such treatment given by IV infusion. Founded in 2004 in Bothell, Washington, by former Celltech researchers, it was later bought by the Danish pharma firm H. Lundbeck and renamed Lundbeck Seattle Biopharmaceuticals. Fun fact: its name comes from the alder tree, a nod to the Pacific Northwest where the company was born.
CONVERTIBLEUnderlying: ALDR1EURCUSIP: 014339AA3HealthcareUS1 derivative reporter
2.50% Convertible Senior Notes due February 1, 2025
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
